Digital health company Noom on Thursday announced it will offer a compounded GLP-1 drug as part of a new weight loss product that starts at $149.
The treatment will feature compounded semaglutide, the same active ingredient in Novo Nordisk‘s blockbuster obesity and diabetes drugs Wegovy and Ozempic. Noom has offered weight loss programs for years, and consumers can already try to access those branded medications through its platform.
But Noom is the latest in a string of digital health companies to offer compounded versions of the medications as a cheaper alternative for consumers while demand for weight loss and diabetes drugs spikes. Hims & Hers and Sesame have launched similar programs in recent months — and the market for low-cost options has grown more competitive.
“Our position is that more supply, especially at a reasonable price, is needed right now, not less,” Noom CEO Geoff Cook told CNBC in an interview.
Wegovy and Ozempic belong to a highly popular class of medications called GLP-1s, which mimic certain gut hormones to tamp down a patient’s appetite and regulate their blood sugar. The compounded versions are custom-made alternatives to the brand drugs, and they can be produced when brand-name treatments are in shortage.
Compounded GLP-1 medications are typically much cheaper than their branded counterparts. Wegovy and Ozempic both cost roughly $1,000 per month before insurance. Most insurance plans cover GLP-1s when they are used to treat diabetes, but coverage of the weight loss drugs is less widespread. Spiking demand can also make it difficult for many patients to find the branded treatments.
Cook said consumers will pay $149 for their first month in Noom’s program and $279 for the following months as the dose of their medication increases.
The U.S. Food and Drug Administration does not review the safety and efficacy of compounded products, and the agency has urged consumers to take the approved, branded GLP-1 medications when they are available. However, the FDA does inspect some outsourcing facilities that compound drugs, according to its website.
Noom said it is working with an FDA-regulated 503B compounding pharmacy to provide its medication for its new program, which is called Noom GLP-1 RX.
“The drug manufacturer we’re working with generates 20 generic medications, epinephrine being one of them — a lifesaving medication that’s available in hospitals all across the United States,” Dr. Adonis Saremi, chief medical officer of Noom, told CNBC in an interview. “So we’re really confident and happy with our vetting process.”
The company said ithas also introduced a way for participants to taper off the compounded treatment if they would like to stop taking it. GLP-1s are intended for long-term use, which means some patients may end up taking them indefinitely.
Cook said Noom has seen both anecdotal and real-world evidence that patients are able to maintain weight loss after they stop taking the drugs. Six out of seven patients are off GLP-1s by the two-year mark anyway, he said.
“It’s prescribed by the doctor, the person takes their medicine, they lose weight, but then life happens,” Cook said. “They eventually stop taking the medication, or their insurance stops covering it, they’ll change a job [so] it’s no longer covered.”
Cook said not everyone will be able to taper off the medication, so some people will likely end up taking it indefinitely. The company will provide a free year of Noom or “substantial medication discounts” to anyone who regains the weight within 18 months after following its program for a year, it said in a release.
Consumers can get started with the Noom GLP-1 RX program by filling out an intake form on the website. Noom said one of its contracted, obesity-trained doctors will review the intake form and decide if the compounded medication is appropriate for that patient. If so, the drugs will arrive at their door within a week, Noom said.
Participants will learn how to inject their medication, and they can use a chat feature to talk one-on-one with a coach and their Noom clinician, the company said. They’ll also have access to a range of psychology-based programming and tools to help keep them from losing muscle mass, such as features for tracking protein intake and engaging in resistance training, Noom said.
And if users decide they are ready to move off the medication, they can chat with their clinician or tap “initiate taper” in their settings, Noom said.
“I think there’s a lot of folks who don’t want to be on a medication for the rest of their lives, and in any event, people aren’t doing that in the real world,” Cook said. “Our goal is just not to sell more medications. It’s to drive sustained weight loss outcomes.”
The SEC filed a lawsuit against Elon Musk on Tuesday, alleging the billionaire committed securities fraud in 2022 by failing to disclose his ownership in Twitter and buying shares at “artificially low prices.”
Musk, who is also CEO of Tesla and SpaceX, purchased Twitter for $44 billion, later changing the name of the social network to X. Prior to the acquisition he’d built up a position in the company of greater than 5%, which would’ve required disclosing his holding to the public.
According to the SEC complaint, filed in U.S. District Court in Washington, D.C., Musk withheld that material information, “allowing him to underpay by at least $150 million for shares he purchased after his financial beneficial ownership report was due.”
The SEC had been investigating whether Musk, or anyone else working with him, committed securities fraud in 2022 as the Tesla CEO sold shares in his car company and shored up his stake in Twitter ahead of his leveraged buyout. Musk said in a post on X last month that the SEC issued a “settlement demand,” pressuring him to agree to a deal including a fine within 48 hours or “face charges on numerous counts” regarding the purchase of shares.
Musk’s lawyer, Alex Spiro, said in an emailed statement that the action is an admission by the SEC that “they cannot bring an actual case.” He added that Musk “has done nothing wrong” and called the suit a “sham” and the result of a “multi-year campaign of harassment,” culminating in a “single-count ticky tak complaint.”
Musk is just a week away from having a potentially influential role in government, as President-elect Donald Trump’s second term begins on Jan. 20. Musk, who was a major financial backer of Trump in the latter stages of the campaign, is poised to lead an advisory group that will focus in part on reducing regulations, including those that affect Musk’s various companies.
In July, Trump vowed to fire SEC chairman Gary Gensler. After Trump’s election victory, Gensler announced that he would be resigning from his post instead.
In a separate civil lawsuit concerning the Twitter deal, the Oklahoma Firefighters Pension and Retirement System sued Musk, accusing him of deliberately concealing his progressive investments in the social network and intent to buy the company. The pension fund’s attorneys argued that Musk, by failing to clearly disclose his investments, had influenced other shareholders’ decisions and put them at a disadvantage.
The SEC said that Musk crossed the 5% ownership threshold in March 2022 and would have been required to disclose his holdings by March 24.
“On April 4, 2022, eleven days after a report was due, Musk finally publicly disclosed his beneficial ownership in a report with the SEC, disclosing that he had acquired over nine percent of Twitter’s outstanding stock,” the complaint says. “That day, Twitter’s stock price increased more than 27% over its previous day’s closing price.”
The SEC alleges that Musk spent over $500 million purchasing more Twitter shares during the time between the required disclosure and the day of his actual filing. That enabled him to buy stock from the “unsuspecting public at artificially low prices,” the complaint says. He “underpaid” Twitter shareholders by over $150 million during that period, according to the SEC.
In the complaint, the SEC is seeking a jury trial and asks that Musk be forced to “pay disgorgement of his unjust enrichment” as well as a civil penalty.
Intel said Tuesday that it plans to spin off Intel Capital, its venture capital wing, into an independent firm, the latest in a series of structural changes announced by the chipmaker.
Turning Intel Capital, which has $5 billion in assets, into a standalone fund will allow it to raise money from outside investors, Intel said. Until now, the venture arm has been fully funded by Intel.
Intel is coming off its worst year on the stock market since the company went public in 1971 due to a series of missteps and hefty market share losses. The company has been cutting costs and simplifying its business as it spends heavily to build cutting-edge chip factories while vying to reinvigorate its PC chip unit.
In December, Intel ousted Pat Gelsinger as CEO following a troubled four-year tenure. He’s been replaced by two interim co-CEOs, David Zinzner and Michelle Holthaus.
Intel sold or wound down a slew of smaller divisions in the past two years under Gelsinger, and laid off employees last year as part of a cost-cutting plan.
Intel is currently spinning off Altera, a company that specializes in simple chips called FPGAs, with plans for it to become a publicly traded company. It also owns the majority of Mobileye, an Israel-based maker of self-driving parts and software. Last year, Intel took several steps in the direction of turning its foundry business into an independent unit, including naming a board of directors.
In Tuesday’s announcement, the company said Intel Capital’s workforce would continue with the investment firm when it becomes independent in the second half of 2025. A representative declined to comment on specific executives’ plans. Intel Capital could also be renamed.
Intel Capital was established in 1991 and was unique at the time as a venture arm of a large corporation.
Since then, that model has been replicated across Silicon Valley and in other industries, with companies including Google, Microsoft, Salesforce, Unilever and BMW jumping into the business. Comcast, the owner of CNBC’s parent, NBCUniversal, started Comcast Ventures in 1999.
While Intel was early to corporate venture capital, it isn’t the first tech company to spin out its investment arm. In 2011, SAP turned SAP Ventures into an independent firm, later naming it Sapphire Ventures.
Corporate venture capital peaked in 2021, when firms in the space raised $156 billion and participated in close to 3,800 deals, according to the National Venture Capital Association. That was the same year that the broader VC market hit record levels, but startup investment numbers have since declined dramatically due largely to higher interest rates, which began going up in 2022.
Executive Chair and CEO of Microsoft Corporation Satya Nadella speaks during the “Microsoft Build: AI Day” event in Jakarta, Indonesia, on April 30, 2024.
Ajeng Dinar Ulfiana | Reuters
Microsoft plans to pause hiring in part of its consulting business in the U.S., according to an internal memo, as the company continues seeking ways to reel in expenses.
The announced cuts come a week after Microsoft said it would lay off some employees. Those cuts will affect less than 1% of the company’s workforce, according to one person familiar with Microsoft’s plans.
Although Microsoft indicated earlier this month that it plans to continue investing in its artificial intelligence efforts, cost cuts elsewhere could lead to gains for the company’s stock price. Microsoft shares increased 12% in 2024, compared with a 29% boost for the Nasdaq Composite index.
The changes by the U.S. consulting division are meant to align with a policy by the Microsoft Customer and Partner Solutions organization, which has about 60,000 employees, according to a page on Microsoft’s website. The changes are in place through the remainder of the 2025 fiscal year ending in June.
To reduce costs, Microsoft’s consulting division will hold off on hiring new employees and back-filling roles, consulting executive Derek Danois told employees in the memo. Careful management of costs is of utmost importance, Danois wrote.
The memo also instructs employees to not expense travel for any internal meetings and use remote sessions instead. Additionally, executives will have to authorize trips to customers’ sites to ensure spending is being used on the right customers, Danois wrote.
Additionally, the group will cut its marketing and non-billable external resource spend by 35%, the memo says.
The consulting division has grown more slowly than Microsoft’s productivity software subscriptions and Azure cloud computing businesses. The consulting unit generated $1.9 billion in the September quarter, down about 1% from one year earlier, compared with 33% for Azure.
Under the leadership of CEO Satya Nadella, Microsoft in early 2023 laid off 10,000 employees and consolidated leases as the company contended with a broader shift in the market and economy. In January 2024, three months after completing the $75.4 billion Activision Blizzard acquisition, Microsoft’s gaming unit shed 1,900 jobs to reduce overlap.
A Microsoft spokesperson did not immediately have a comment.